ClinicalTrials.gg
TerminatedNCT03092791Updated Jan 31, 2020Results posted

IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults

A Phase 1/2 interventional study of Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV) and Reference IPV in Poliomyelitis, sponsored by Takeda. Terminated at 4 sites in Panama. Open to participants aged 6 Weeks to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-31.

Sponsored by Takeda · Phase 1/2, Interventional, and Prevention

Why this study was terminated
Planned immunogenicity outcomes not reached

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
6 Weeks to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Poliomyelitis with a site in Panama — 2 open to participants now, 2 under way, none of them phase 3. Poliomyelitis · Panama.

Enrollment
8th of 10
340 · median 724
Started
2017
with 2 others
Phase 1/2
Only one
of the 10
Registered
4th of 10
by date
Lead sponsor
1 of 10
Takeda

Among the 10 studies in Poliomyelitis with a site in Panama, this one is the 8th largest by enrollment, is one of 3 that started in 2017, is the only one in phase 1/2, and was the 4th registered.

Poliomyelitis

275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.

Browse Poliomyelitis studies →

Open to participants now

2 of the 10 studies in Poliomyelitis with a site in Panama are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Panama have not opened yet or have stopped. Only those recruiting at a site in Panama →

Who these studies take

Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 6 Weeks to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Poliomyelitis with a site in Panama, or all of them as a file.
02

Study summary

The purpose of this study is to select the optimal antigen dosage of the three Sabin poliovirus strains (types 1, 2, and 3) entering the composition of the stand-alone trivalent Sabin-based inactivated poliomyelitis vaccine (sIPV) to take forward into advanced stage studies. The selection will be carried out comparing the three sIPV study arms based on the safety and tolerability profile after each dose of primary immunization and the immune response to poliovirus types 1, 2, and 3 for both Sabin and Salk strains, after the final dose of a three dose primary immunization series (Day 85).

Read the detailed description

The vaccine being tested in this study is called sIPV. sIPV is used to prevent poliomyelitis. This study will look at the safety, tolerability of sIPV in healthy adults, toddlers and infants as well as safety and immunogenicity in toddlers and infants. .

The study will enroll approximately 340 participants including 40 adults, 60 toddlers and 240 infants. Adult participants will be randomly assigned to one of the two treatment groups-which will remain undisclosed to study doctor and participants during the study (unless there is an urgent medical need):

  • sIPV High Dose
  • Placebo (saline control - 0.9% sodium chloride)

Toddler participants will be randomly assigned to one of the following treatment groups:

  • sIPV High Dose
  • Reference IPV

Infant participants will be randomly assigned to one of following treatment groups:

  • sIPV Low Dose
  • sIPV Medium Dose
  • sIPV High Dose
  • Reference IPV Adults and toddlers will receive intramuscular injection on Day 1. Infants will receive intramuscular injection on Days 1, 29, 57 and 365.

This is a multicentre trial. The overall time to participate in this study for adult is 8 days, for toddlers is 183 days and infants is 547 days.

03

Conditions studied

  • Poliomyelitis

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
6 Weeks to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult Lead-in Cohort

  1. Individuals who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.
  2. Completed primary immunization against poliomyelitis according to local recommendations.

Toddler Lead-in Cohort

  1. Toddlers in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.
  2. Completed primary immunization against poliomyelitis, preferably with IPV, according to local recommendations.

Infant Dose Ranging Cohort 1. Infants are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.

  1. Infants must have been born full term (37-42 weeks of gestation).

Exclusion criteria

Exclusion Criteria:

Adult Lead-in Cohort

  1. Has (BMI) greater than or equal to 35 kg/m\^2 (= weight in kg [height in meters * height in meters].

Toddler Lead-in Cohort

  1. Last polio vaccination (either inactivated or oral) received within 5 months prior to first trial visit.
  2. Household member/sibling who had received or is/are scheduled to receive Oral Poliomyelitis Vaccine (OPV) in the previous 3 months until 5 weeks post participant's inclusion in the study.
  3. Prior vaccination with booster dose of diphtheria, tetanus, pertussis (acellular or whole cell), polio (either inactivated or oral), or Haemophilus influenzae type b (Hib) vaccines.

Infant Dose Ranging Cohort

  1. Infants with low birth weight according to local standards.
  2. Prior vaccination with polio vaccines (either inactivated or oral).
  3. Household member/sibling that had received or is/are scheduled to receive OPV in the previous 3 months until 5 weeks after the third dose of the primary immunization series.
  4. Prior vaccination with any diphtheria, tetanus, pertussis (acellular or whole cell), Haemophilus influenzae type b (Hib) vaccine or polio vaccine (OPV or IPV). Note, bacillus Calmette Guérin (BCG) at birth and prior vaccination with vaccine given at least 4 weeks prior to first trial visit are not exclusion criteria.

All Cohorts

  1. Any significant chronic infection.
  2. Any active infection (as assessed by the investigator) or temperature ≥38.0°C (>100.4°F), within 3 days of intended trial vaccination.
  3. Known or suspected impairment/alteration of immune function, including:

    1. Chronic use of oral (equivalent to 20 mg/day prednisone for ≥12 weeks/≥2 mg/kg body weight/day for ≥2 weeks) within 60 days prior to Day 1 (use of inhaled, intranasal, or topical corticosteroids is allowed).
    2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day for ≥2 weeks) within 60 days prior to Day 1.
    3. Administration of immunoglobulins and/or any blood or blood products within the 3 months preceding the administration of the trial vaccine or planned administration during the trial
    4. Receipt of immunostimulants within 60 days prior to Day 1.
    5. Genetic immunodeficiency.
  4. Has a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
340 participants (actual)

Study arms

  • Experimental
    Adult Lead-in Cohort: sIPV High Dose

    Sabin-based inactivated poliomyelitis vaccine (sIPV) containing 3, 100, and 100 D-Ag units (DU) of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.

    Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

  • Placebo comparator
    Adult Lead-in Cohort: Placebo

    Placebo, intramuscular injection on Day 1.

    Biological: sIPV Placebo

  • Experimental
    Toddler Lead-in Cohort: sIPV High Dose

    sIPV containing 3, 100, and 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.

    Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

  • Active comparator
    Toddler Lead-in Cohort: Reference IPV

    Reference IPV, intramuscular injection on Day 1.

    Biological: Reference IPV

  • Experimental
    Infant Dose Ranging Cohort: sIPV Low Dose

    sIPV containing 0.75, 25, 25 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29, 57 and 365.

    Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

  • Experimental
    Infant Dose Ranging Cohort: sIPV Medium Dose

    sIPV containing 1.5, 50, 50 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.

    Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

  • Experimental
    Infant Dose Ranging Cohort: sIPV High Dose

    sIPV containing 3, 100, 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.

    Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

  • Active comparator
    Infant Dose Ranging Cohort: Reference IPV

    Reference IPV, intramuscular injection on Days 1, 29 57 and 365.

    Biological: Reference IPV

Interventions

  • BiologicalSabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

    sIPV intramuscular injection

  • BiologicalReference IPV

    Reference IPV intramuscular injection

  • BiologicalsIPV Placebo

    sIPV placebo-matching intramuscular injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After First Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 1

    Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm). Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 days of the First Dose given on Day 1

  2. Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Second Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 29

    Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm). Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 days of the Second Dose given on Day 29

  3. Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Third Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 57

    Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm). Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 Days of the Third Dose given on Day 57

  4. Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After First Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 1

    Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 days of the First Dose given on Day 1

  5. Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After Second Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 29

    Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 days of the Second Dose given on Day 29

  6. Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After Third Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 57

    Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 Days of the Third Dose given on Day 57

  7. Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After First Primary Immunization Dose of sIPV on Day 1

    A systemic adverse event (AE) of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 days of the First Dose given on Day 1

  8. Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Second Primary Immunization Dose of sIPV on Day 29

    A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 days of the Second Dose given on Day 29

  9. Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Third Primary Immunization Dose of sIPV on Day 57

    A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 days of the Third Dose given on Day 57

  10. Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort

    An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.

    Time frame: Within 28 days of primary vaccinations given on Days 1, 29 and 57 (Up to Day 85)

  11. Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in the sIPV Study Arms in Infant Dose Ranging Cohort

    An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.

    Time frame: Day 1 up to Day 547

  12. Percentage of Participants With Seroconversion

    Seroconversion is defined as i) initially seronegative infants (titer \<8 at Day 1) having a titer ≥8 at Day 85, or ii) initially seropositive infants (titer ≥8 at Day 1) with a 4-fold rise in antibody titers over the expected level of maternal antibodies at Day 85, calculated using a decline from the Day 1 titer with a half-life of 28 days.

    Time frame: Day 85

Secondary outcomes

  1. Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV by Severity in Infant Dose Ranging Cohort

    Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (0-none, 1-mild: Minor reaction to touch, 2-moderate: Cries/protests on touch, 3-severe: Cries when limb is moved/spontaneously painful), erythema, induration and swelling (0: \<10 mm, 1-Mild: \>10 - ≤ 20 mm, 2-Moderate: \> 20 - ≤ 40 mm, 3-Severe: \> 40 mm). Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 days of primary vaccinations (First Dose given on Day 1, Second Dose given on Day 29, Third Dose given on Day 57)

  2. Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV by Severity in Infant Dose Ranging Cohort

    Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 days of primary vaccinations (First Dose given on Day 1, Second Dose given on Day 29, Third Dose given on Day 57)

  3. Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV in Infant Dose Ranging Cohort

    A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 days of primary vaccinations (First Dose given on Day 1, Second Dose given on Day 29, Third Dose given on Day 57)

  4. Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV in Infant Dose Ranging Cohort

    An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.

    Time frame: Within 28 Days of primary vaccinations (Up to 85 days)

  5. Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in the sIPV or IPV Study Arms in Infant Dose Ranging Cohort

    An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.

    Time frame: Day 1 up to Day 547

  6. Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Booster Vaccination in Infant Dose Ranging Cohort

    Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (0-none, 1-mild: Minor reaction to touch, 2-moderate: Cries/protests on touch, 3-severe: Cries when limb is moved/spontaneously painful), erythema, induration and swelling (0: \<10 mm, 1-Mild: \>10 - ≤ 20 mm, 2-Moderate: \> 20 - ≤ 40 mm, 3-Severe: \> 40 mm).

    Time frame: Within 7 days of booster vaccination given on Day 365

  7. Percentage of Participants With Solicited Systemic AEs Within 7-day Period (Including Day of Vaccination) After Booster Vaccination in Infant Dose Ranging Cohort

    Percentage of participants with solicited systemic adverse events on a symptom by symptom basis, in each severity category will be reported. Solicited systemic adverse events include drowsiness, irritability/fussiness, loss of appetite, and fever. Fever is defined as greater than or equal to 38°C (100.4°F) regardless of method used.

    Time frame: Within 7 days of booster vaccination given on Day 365

  8. Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Booster Vaccination in Infant Dose Ranging Cohort

    Fever is defined as greater than or equal to 38°C (100.4°F) regardless of method used.

    Time frame: Within 7 days of booster vaccination given on Day 365

  9. Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Booster Vaccination in Infant Dose Ranging Cohort

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than SAEs) that occurred other than those that are solicited.

    Time frame: Within 28 days of booster vaccination given on Day 365

  10. Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Booster Vaccination in Toddler Lead-in Cohort

    Percentage of participants with solicited local reactions on a symptom by symptom basis, in each severity category will be reported. Solicited local reactions include pain, erythema, induration and swelling.

    Time frame: Within 7 days of booster vaccination given on Day 365

  11. Percentage of Participants With Solicited Systemic AEs Within 7-day Period (Including Day of Vaccination) After Booster Vaccination in Toddler Lead-in Cohort

    Percentage of participants with solicited systemic adverse events on a symptom by symptom basis, in each severity category will be reported. Solicited systemic adverse events include headache, asthenia, malaise, arthralgia, myalgia.

    Time frame: Within 7 days of booster vaccination given on Day 365

  12. Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Booster Vaccination in Toddler Lead-in Cohort

    Fever is defined as greater than or equal to 38°C (100.4°F) regardless of method used.

    Time frame: Within 7 days of booster vaccination given on Day 365

  13. Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Booster Vaccination in Toddler Lead-in Cohort

    An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.

    Time frame: Within 28 Days of booster vaccination given on Day 365

  14. Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in Toddler Lead-in Cohort

    An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.

    Time frame: Day 1 up to Day 183

  15. Number of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort

    Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm).

    Time frame: Within 7 days of sIPV or placebo vaccination

  16. Number of Participants With Solicited Systemic AEs Within 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort

    Solicited systemic AEs were collected by participants within 7 days after vaccination and included headache, asthenia, malaise, arthralgia and myalgia and fever. Severity scales for headache were none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents normal activity with or without treatment. Severity scales for others were none, mild: no interference with daily activity, moderate: interference with daily activity and severe: prevents daily activity. Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 days of sIPV or placebo vaccination

  17. Number of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort

    A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each immunization. Data is only reported for those categories with at least 1 participant.

    Time frame: Within 7 days of sIPV or placebo vaccination dose given on Day 1

  18. Number of Participants Experiencing Non-serious Unsolicited AEs Within the 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort

    An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.

    Time frame: Within 7 days of sIPV or placebo vaccination

  19. Number of Participants Experiencing SAEs Throughout the Entire Trial Duration in Adult Lead-in Cohort

    An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.

    Time frame: Day 1 up to Day 8

  20. Seropositivity/Seroprotection Rate (SPR) on Days 85, 365 and 393 in Infant Dose Ranging Cohort

    SPR is defined as the percentage of participants with antibodies titers of poliovirus types 1, 2, and 3 for both Sabin and Salk strain ≥8.

    Time frame: Days 85, 365 and 393

  21. Geometric Mean Titers (GMT) on Days 85, 365 and 393 in Infant Dose Ranging Cohort

    GMT titers for poliovirus types 1, 2, and 3 for both Sabin and Salk strains will be reported.

    Time frame: Days 85, 365 and 393

  22. Vaccine Response Rate (VRR) on Day 393 in Infant Dose Ranging Cohort

    VRR is defined as percentage of participants i) seronegative prior to booster vaccination (titer \<8) having a titer ≥8, or ii) seropositive prior to booster vaccination (titer ≥8) having a 4-fold rise in antibody titers.

    Time frame: Day 393

07

Results

Posted Jan 31, 2020

Participant flow

Participants took part in the study at four investigative sites in Panama from 7 June 2017 to 18 October 2018.

Participant flow — Overall Study
MilestoneAdult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: PlaceboToddler Lead-in Cohort: sIPV High DoseToddler Lead-in Cohort: Reference IPVInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPV
Started2020303060606060
Completed202030300000
Not completed000060606060
Withdrew: Lost to follow-up00000010
Withdrew: Withdrawal of consent000041264
Withdrew: Study termination000055465355
Withdrew: Death00000101
Withdrew: Reason not specified00001100

Outcome measures

PrimaryPercentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After First Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 1

Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm). Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 days of the First Dose given on Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After First Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 1
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High Dose
Pain: First Dose (Day 1), Any84.269.280.4
Pain: First Dose (Day 1), Mild26.330.841.1
Pain: First Dose (Day 1), Moderate31.617.325.0
Pain: First Dose (Day 1), Severe26.321.214.3
Erythema: First Dose (Day 1), Any5.31.90
Induration: First Dose (Day 1), Any1.83.90
Induration: First Dose (Day 1), Moderate02.00
Swelling: First Dose (Day 1), Any1.87.80
Swelling: First Dose (Day 1), Moderate02.00
PrimaryPercentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Second Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 29

Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm). Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 days of the Second Dose given on Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Second Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 29
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High Dose
Pain: Second Dose (Day 29), Any48.247.961.8
Pain: Second Dose (Day 29), Mild30.425.036.4
Pain: Second Dose (Day 29), Moderate14.316.718.2
Pain: Second Dose (Day 29), Severe3.66.37.3
Erythema: Second Dose (Day 29), Any1.82.10
Induration: Second Dose (Day 29), Any02.10
Swelling: Second Dose (Day 29), Any04.20
Swelling: Second Dose (Day 29), Mild02.10
PrimaryPercentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Third Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 57

Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm). Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 Days of the Third Dose given on Day 57
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Third Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 57
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High Dose
Pain: Third Dose (Day 57), Any46.444.449.1
Pain: Third Dose (Day 57), Mild33.931.134.0
Pain: Third Dose (Day 57), Moderate8.98.911.3
Pain: Third Dose (Day 57), Severe3.64.43.8
Erythema: Third Dose (Day 57), Any02.21.9
Swelling: Third Dose (Day 57), Any1.800
PrimaryPercentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After First Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 1

Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 days of the First Dose given on Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After First Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 1
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High Dose
Drowsiness: First Dose (Day 1), Any49.148.147.3
Drowsiness: First Dose (Day 1), Mild38.632.723.6
Drowsiness: First Dose (Day 1), Moderate8.813.521.8
Drowsiness: First Dose (Day 1), Severe1.81.91.8
Irritability: First Dose (Day 1), Any56.157.758.2
Irritability: First Dose (Day 1), Mild28.128.829.1
Irritability: First Dose (Day 1), Moderate21.119.218.2
Irritability: First Dose (Day 1), Severe7.09.610.9
Loss of Appetite: First Dose (Day 1), Any29.825.021.8
Loss of Appetite: First Dose (Day 1), Mild26.323.19.1
Loss of Appetite: First Dose (Day 1), Moderate3.51.912.7
PrimaryPercentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After Second Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 29

Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 days of the Second Dose given on Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After Second Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 29
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High Dose
Drowsiness: Second Dose (Day 29), Any30.420.836.4
Drowsiness: Second Dose (Day 29), Mild19.618.825.5
Drowsiness: Second Dose (Day 29), Moderate10.72.110.9
Irritability: Second Dose (Day 29), Any37.533.345.5
Irritability: Second Dose (Day 29), Mild19.625.030.9
Irritability: Second Dose (Day 29), Moderate10.76.39.1
Irritability: Second Dose (Day 29), Severe7.12.15.5
Loss of Appetite: Second Dose (Day 29), Any14.310.418.2
Loss of Appetite: Second Dose (Day 29), Mild12.58.316.4
Loss of Appetite: Second Dose (Day 29), Moderate1.82.10
Loss of Appetite: Second Dose (Day 29), Severe001.8
PrimaryPercentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After Third Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 57

Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 Days of the Third Dose given on Day 57
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After Third Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort by Severity on Day 57
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High Dose
Drowsiness: Third Dose (Day 57), Any38.221.732.1
Drowsiness: Third Dose (Day 57), Mild25.521.726.4
Drowsiness: Third Dose (Day 57), Moderate12.705.7
Irritability: Third Dose (Day 57), Any40.026.137.7
Irritability: Third Dose (Day 57), Mild27.321.728.3
Irritability: Third Dose (Day 57), Moderate5.52.27.5
Irritability: Third Dose (Day 57), Severe7.32.21.9
Loss of Appetite: Third Dose (Day 57), Any10.96.513.2
Loss of Appetite: Third Dose (Day 57), Mild9.16.513.2
Loss of Appetite: Third Dose (Day 57), Moderate1.800
PrimaryPercentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After First Primary Immunization Dose of sIPV on Day 1

A systemic adverse event (AE) of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 days of the First Dose given on Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After First Primary Immunization Dose of sIPV on Day 1
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High Dose
Fever: First Dose (Day 1), Any15.817.323.6
Fever: First Dose (Day 1), 38.0°C - 38.4°C8.89.614.5
Fever: First Dose (Day 1), 38.5°C - 38.9°C7.07.79.1
PrimaryPercentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Second Primary Immunization Dose of sIPV on Day 29

A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 days of the Second Dose given on Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Second Primary Immunization Dose of sIPV on Day 29
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High Dose
Fever: Second Dose (Day 29), Any7.16.414.8
Fever: Second Dose (Day 29), 38.0°C - 38.4°C3.62.111.1
Fever: Second Dose (Day 29), 38.5°C - 38.9°C3.62.13.7
Fever: Second Dose (Day 29), 39.0°C - 39.4°C02.10
PrimaryPercentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Third Primary Immunization Dose of sIPV on Day 57

A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 days of the Third Dose given on Day 57
Reported as:
Number · percentage of participants
Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Third Primary Immunization Dose of sIPV on Day 57
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High Dose
Fever: Third Dose (Day 57), Any9.18.715.4
Fever: Third Dose (Day 57), 38.0°C - 38.4°C9.16.53.8
Fever: Third Dose (Day 57), 38.5°C - 38.9°C007.7
Fever: Third Dose (Day 57), 39.0°C - 39.4°C02.21.9
Fever: Third Dose (Day 57), 39.5°C - 39.9°C001.9
PrimaryPercentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort

An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.

Time frame:
Within 28 days of primary vaccinations given on Days 1, 29 and 57 (Up to Day 85)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High Dose
Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV in Infant Dose Ranging Cohort28.828.331.7
PrimaryPercentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in the sIPV Study Arms in Infant Dose Ranging Cohort

An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.

Time frame:
Day 1 up to Day 547
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in the sIPV Study Arms in Infant Dose Ranging Cohort
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High Dose
Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in the sIPV Study Arms in Infant Dose Ranging Cohort13.68.38.3
PrimaryPercentage of Participants With Seroconversion

Seroconversion is defined as i) initially seronegative infants (titer \<8 at Day 1) having a titer ≥8 at Day 85, or ii) initially seropositive infants (titer ≥8 at Day 1) with a 4-fold rise in antibody titers over the expected level of maternal antibodies at Day 85, calculated using a decline from the Day 1 titer with a half-life of 28 days.

Time frame:
Day 85
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPV
Sabin Type 1: Day 8563.0 (48.7 to 75.7)77.8 (62.9 to 88.8)86.0 (73.3 to 94.2)92.5 (81.8 to 97.9)
Sabin Type 2: Day 8568.5 (54.4 to 80.5)77.8 (62.9 to 88.8)90.0 (78.2 to 96.7)94.3 (84.3 to 98.8)
Sabin Type 3, Day 8596.3 (87.3 to 99.5)100 (92.1 to 100)96.0 (86.3 to 99.5)96.2 (87.0 to 99.5)
Salk Type 1: Day 8537.0 (24.3 to 51.3)53.3 (37.9 to 68.3)68.0 (53.3 to 80.5)96.2 (87.0 to 99.5)
Salk Type 2: Day 8535.2 (22.7 to 49.4)55.6 (40.0 to 70.4)70.0 (55.4 to 82.1)96.2 (87.0 to 99.5)
Salk Type 3: Day 8590.7 (79.7 to 96.9)93.3 (81.7 to 98.6)94.0 (83.5 to 98.7)94.3 (84.3 to 98.8)
SecondaryPercentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV by Severity in Infant Dose Ranging Cohort

Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (0-none, 1-mild: Minor reaction to touch, 2-moderate: Cries/protests on touch, 3-severe: Cries when limb is moved/spontaneously painful), erythema, induration and swelling (0: \<10 mm, 1-Mild: \>10 - ≤ 20 mm, 2-Moderate: \> 20 - ≤ 40 mm, 3-Severe: \> 40 mm). Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 days of primary vaccinations (First Dose given on Day 1, Second Dose given on Day 29, Third Dose given on Day 57)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV by Severity in Infant Dose Ranging Cohort
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPV
Pain: First Dose (Day 1), Any84.269.280.486.0
Pain: First Dose (Day 1), Mild26.330.841.122.8
Pain: First Dose (Day 1), Moderate31.617.325.040.4
Pain: First Dose (Day 1), Severe26.321.214.322.8
Erythema: First Dose (Day 1), Any5.31.901.8
Induration: First Dose (Day 1), Any1.83.901.8
Induration: First Dose (Day 1), Moderate02.000
Swelling: First Dose (Day 1), Any1.87.801.8
Swelling: First Dose (Day 1), Moderate02.000
Pain: Second Dose (Day 29), Any48.247.961.859.6
Pain: Second Dose (Day 29), Mild30.425.036.445.6
Pain: Second Dose (Day 29), Moderate14.316.718.28.8
Pain: Second Dose (Day 29), Severe3.66.37.35.3
Erythema: Second Dose (Day 29), Any1.82.100
Induration: Second Dose (Day 29), Any02.100
Swelling: Second Dose (Day 29), Any04.200
Swelling: Second Dose (Day 29), Mild02.100
Pain: Third Dose (Day 57), Any46.444.449.160.7
Pain: Third Dose (Day 57), Mild33.931.134.048.2
Pain: Third Dose (Day 57), Moderate8.98.911.38.9
Pain: Third Dose (Day 57), Severe3.64.43.83.6
Erythema: Third Dose (Day 57), Any02.21.91.8
Induration: Third Dose (Day 57), Any0001.8
Swelling: Third Dose (Day 57), Any1.8000
SecondaryPercentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV by Severity in Infant Dose Ranging Cohort

Solicited systemic AEs were collected within 7 days after vaccination using a diary and included drowsiness, graded as 0-behavior as usual, 1-mild: drowsiness easily tolerated, 2-moderate: drowsiness that interferes with normal activity and 3-severe: prevents normal activity with or without treatment; irritability/fussiness, graded as 0-behavior as usual, mild: crying more than usual/no effect on normal activity, moderate: crying more than usual/interferes with normal activity and severe: crying that cannot be comforted/prevents normal; loss of appetite, graded as 0-apetite as usual, mild: eating less than usual/no effect on normal activity, moderate: eating less than usual/interferes with normal activity and severe: not eating at all. Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 days of primary vaccinations (First Dose given on Day 1, Second Dose given on Day 29, Third Dose given on Day 57)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV by Severity in Infant Dose Ranging Cohort
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPV
Drowsiness: First Dose (Day 1), Any49.148.147.344.6
Drowsiness: First Dose (Day 1), Mild38.632.723.626.8
Drowsiness: First Dose (Day 1), Moderate8.813.521.816.1
Drowsiness: First Dose (Day 1), Severe1.81.91.81.8
Irritability: First Dose (Day 1), Any56.157.758.261.4
Irritability: First Dose (Day 1), Mild28.128.829.128.1
Irritability: First Dose (Day 1), Moderate21.119.218.222.8
Irritability: First Dose (Day 1), Severe7.09.610.910.5
Loss of Appetite: First Dose (Day 1), Any29.825.021.819.3
Loss of Appetite: First Dose (Day 1), Mild26.323.19.18.8
Loss of Appetite: First Dose (Day 1), Moderate3.51.912.710.5
Drowsiness: Second Dose (Day 29), Any30.420.836.429.8
Drowsiness: Second Dose (Day 29), Mild19.618.825.522.8
Drowsiness: Second Dose (Day 29), Moderate10.72.110.97.0
Irritability: Second Dose (Day 29), Any37.533.345.538.6
Irritability: Second Dose (Day 29), Mild19.625.030.926.3
Irritability: Second Dose (Day 29), Moderate10.76.39.18.8
Irritability: Second Dose (Day 29), Severe7.12.15.53.5
Loss of Appetite: Second Dose (Day 29), Any14.310.418.28.8
Loss of Appetite: Second Dose (Day 29), Mild12.58.316.48.8
Loss of Appetite: Second Dose (Day 29), Moderate1.82.100
Loss of Appetite: Second Dose (Day 29), Severe001.80
Drowsiness: Third Dose (Day 57), Any38.221.732.125.0
Drowsiness: Third Dose (Day 57), Mild25.521.726.416.1
Drowsiness: Third Dose (Day 57), Moderate12.705.78.9
Irritability: Third Dose (Day 57), Any40.026.137.733.9
Irritability: Third Dose (Day 57), Mild27.321.728.326.8
Irritability: Third Dose (Day 57), Moderate5.52.27.57.1
Irritability: Third Dose (Day 57), Severe7.32.21.90
Loss of Appetite: Third Dose (Day 57), Any10.96.513.28.9
Loss of Appetite: Third Dose (Day 57), Mild9.16.513.23.6
Loss of Appetite: Third Dose (Day 57), Moderate1.8003.6
Loss of Appetite: Third Dose (Day 57), Severe0001.8
SecondaryPercentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV in Infant Dose Ranging Cohort

A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each Immunization. Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 days of primary vaccinations (First Dose given on Day 1, Second Dose given on Day 29, Third Dose given on Day 57)
Reported as:
Number · percentage of participants
Percentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV in Infant Dose Ranging Cohort
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPV
Fever: First Dose (Day 1), Any15.817.323.633.3
Fever: First Dose (Day 1), 38.0°C - 38.4°C8.89.614.515.8
Fever: First Dose (Day 1), 38.5°C - 38.9°C7.07.79.115.8
Fever: First Dose (Day 1), >= 40.0°C0001.8
Fever: Second Dose (Day 29), Any7.16.414.810.5
Fever: Second Dose (Day 29), 38.0°C - 38.4°C3.62.111.17.0
Fever: Second Dose (Day 29), 38.5°C - 38.9°C3.62.13.73.5
Fever: Second Dose (Day 29), 39.0°C - 39.4°C02.100
Fever: Third Dose (Day 57), Any9.18.715.412.5
Fever: Third Dose (Day 57), 38.0°C - 38.4°C9.16.53.87.1
Fever: Third Dose (Day 57), 38.5°C - 38.9°C007.75.4
Fever: Third Dose (Day 57), 39.0°C - 39.4°C02.21.90
Fever: Third Dose (Day 57), 39.5°C - 39.9°C001.90
SecondaryPercentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV in Infant Dose Ranging Cohort

An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.

Time frame:
Within 28 Days of primary vaccinations (Up to 85 days)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV in Infant Dose Ranging Cohort
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPV
Percentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Each Primary Immunization Dose of sIPV or IPV in Infant Dose Ranging Cohort28.828.331.733.3
SecondaryPercentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in the sIPV or IPV Study Arms in Infant Dose Ranging Cohort

An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.

Time frame:
Day 1 up to Day 547
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in the sIPV or IPV Study Arms in Infant Dose Ranging Cohort
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPV
Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in the sIPV or IPV Study Arms in Infant Dose Ranging Cohort13.68.38.313.3
SecondaryPercentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Booster Vaccination in Infant Dose Ranging Cohort

Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (0-none, 1-mild: Minor reaction to touch, 2-moderate: Cries/protests on touch, 3-severe: Cries when limb is moved/spontaneously painful), erythema, induration and swelling (0: \<10 mm, 1-Mild: \>10 - ≤ 20 mm, 2-Moderate: \> 20 - ≤ 40 mm, 3-Severe: \> 40 mm).

Time frame:
Within 7 days of booster vaccination given on Day 365

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Solicited Systemic AEs Within 7-day Period (Including Day of Vaccination) After Booster Vaccination in Infant Dose Ranging Cohort

Percentage of participants with solicited systemic adverse events on a symptom by symptom basis, in each severity category will be reported. Solicited systemic adverse events include drowsiness, irritability/fussiness, loss of appetite, and fever. Fever is defined as greater than or equal to 38°C (100.4°F) regardless of method used.

Time frame:
Within 7 days of booster vaccination given on Day 365

No measurements were reported for this outcome.

SecondaryPercentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Booster Vaccination in Infant Dose Ranging Cohort

Fever is defined as greater than or equal to 38°C (100.4°F) regardless of method used.

Time frame:
Within 7 days of booster vaccination given on Day 365

No measurements were reported for this outcome.

SecondaryPercentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Booster Vaccination in Infant Dose Ranging Cohort

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than SAEs) that occurred other than those that are solicited.

Time frame:
Within 28 days of booster vaccination given on Day 365

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After Booster Vaccination in Toddler Lead-in Cohort

Percentage of participants with solicited local reactions on a symptom by symptom basis, in each severity category will be reported. Solicited local reactions include pain, erythema, induration and swelling.

Time frame:
Within 7 days of booster vaccination given on Day 365

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Solicited Systemic AEs Within 7-day Period (Including Day of Vaccination) After Booster Vaccination in Toddler Lead-in Cohort

Percentage of participants with solicited systemic adverse events on a symptom by symptom basis, in each severity category will be reported. Solicited systemic adverse events include headache, asthenia, malaise, arthralgia, myalgia.

Time frame:
Within 7 days of booster vaccination given on Day 365

No measurements were reported for this outcome.

SecondaryPercentage of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After Booster Vaccination in Toddler Lead-in Cohort

Fever is defined as greater than or equal to 38°C (100.4°F) regardless of method used.

Time frame:
Within 7 days of booster vaccination given on Day 365

No measurements were reported for this outcome.

SecondaryPercentage of Participants Experiencing Non-serious Unsolicited AEs Within the 28-day Period (Including Day of Vaccination) After Booster Vaccination in Toddler Lead-in Cohort

An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.

Time frame:
Within 28 Days of booster vaccination given on Day 365

No measurements were reported for this outcome.

SecondaryPercentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in Toddler Lead-in Cohort

An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.

Time frame:
Day 1 up to Day 183
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in Toddler Lead-in Cohort
percentage of participantsToddler Lead-in Cohort: sIPV High DoseToddler Lead-in Cohort: Reference IPV
Percentage of Participants Experiencing SAEs Throughout the Entire Trial Duration in Toddler Lead-in Cohort00
SecondaryNumber of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort

Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included pain (none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment, severe: prevents daily activity with or without treatment), erythema, induration and swelling (any: \<25 mm, mild: \>25 - ≤ 50 mm, moderate: \> 50 - ≤ 100 mm, severe: \> 100 mm).

Time frame:
Within 7 days of sIPV or placebo vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local Reactions Within 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort
ParticipantsAdult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: Placebo
Pain: First Dose (Day 1), Any94
Pain: First Dose (Day 1), Mild74
Pain: First Dose (Day 1), Moderate20
Erythema: First Dose (Day 1), Any10
Induration: First Dose (Day 1), Any01
Induration: First Dose (Day 1), Mild01
Swelling: First Dose (Day 1), Any01
Swelling: First Dose (Day 1), Mild01
SecondaryNumber of Participants With Solicited Systemic AEs Within 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort

Solicited systemic AEs were collected by participants within 7 days after vaccination and included headache, asthenia, malaise, arthralgia and myalgia and fever. Severity scales for headache were none, mild: no interference with daily activity, moderate: interference with daily activity with or without treatment and severe: prevents normal activity with or without treatment. Severity scales for others were none, mild: no interference with daily activity, moderate: interference with daily activity and severe: prevents daily activity. Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 days of sIPV or placebo vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic AEs Within 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort
ParticipantsAdult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: Placebo
Headache: First Dose (Day 1), Any33
Headache: First Dose (Day 1), Mild13
Headache: First Dose (Day 1), Moderate10
Headache: First Dose (Day 1), Severe10
Malaise: First Dose (Day 1), Any11
Malaise: First Dose (Day 1), Mild01
Malaise: First Dose (Day 1), Moderate10
Arthralgia: First Dose (Day 1), Any43
Arthralgia: First Dose (Day 1), Mild21
Myalgia: First Dose (Day 1), Any43
Myalgia: First Dose (Day 1), Mild22
Myalgia: First Dose (Day 1), Moderate21
SecondaryNumber of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort

A systemic AE of fever (defined as ≥38°C or ≥100.4°F) was derived from a daily temperature reading recorded within 7 days after each immunization. Data is only reported for those categories with at least 1 participant.

Time frame:
Within 7 days of sIPV or placebo vaccination dose given on Day 1
Reported as:
Count of participants · Participants
Number of Participants With a Body Temperature ≥ 38°C (Defined as Fever) During the 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort
ParticipantsAdult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: Placebo
Fever: First Dose (Day 1), Any01
Fever: First Dose (Day 1), 38.5°C - 38.9°C01
SecondaryNumber of Participants Experiencing Non-serious Unsolicited AEs Within the 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort

An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. Non-serious unsolicited AEs indicates any and all AEs (other than serious adverse events \[SAEs\]) that occurred other than those that are solicited.

Time frame:
Within 7 days of sIPV or placebo vaccination
Reported as:
Count of participants · Participants
Number of Participants Experiencing Non-serious Unsolicited AEs Within the 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort
ParticipantsAdult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: Placebo
Number of Participants Experiencing Non-serious Unsolicited AEs Within the 7-day Period (Including Day of Vaccination) After a Single Dose of sIPV or Placebo in Adult Lead-in Cohort00
SecondaryNumber of Participants Experiencing SAEs Throughout the Entire Trial Duration in Adult Lead-in Cohort

An SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.

Time frame:
Day 1 up to Day 8
Reported as:
Count of participants · Participants
Number of Participants Experiencing SAEs Throughout the Entire Trial Duration in Adult Lead-in Cohort
ParticipantsAdult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: Placebo
Number of Participants Experiencing SAEs Throughout the Entire Trial Duration in Adult Lead-in Cohort00
SecondarySeropositivity/Seroprotection Rate (SPR) on Days 85, 365 and 393 in Infant Dose Ranging Cohort

SPR is defined as the percentage of participants with antibodies titers of poliovirus types 1, 2, and 3 for both Sabin and Salk strain ≥8.

Time frame:
Days 85, 365 and 393
Reported as:
Number · percentage of participants
Seropositivity/Seroprotection Rate (SPR) on Days 85, 365 and 393 in Infant Dose Ranging Cohort
percentage of participantsInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPV
Sabin Type 1: Day 8572.2 (58.4 to 83.5)89.1 (76.4 to 96.4)88.0 (75.7 to 95.5)96.2 (87.0 to 99.5)
Sabin Type 2: Day 8583.3 (70.7 to 92.1)95.7 (85.2 to 99.5)100 (92.9 to 100)98.1 (89.9 to 100)
Sabin Type 3: Day 8598.1 (90.1 to 100)100 (92.3 to 100)98.0 (89.4 to 99.9)100 (93.3 to 100)
Salk Type 1: Day 8542.6 (29.2 to 56.8)56.5 (41.1 to 71.1)72.0 (57.5 to 83.8)96.2 (87.0 to 99.5)
Salk Type 2: Day 8538.9 (25.9 to 53.1)65.2 (49.8 to 78.6)74.0 (59.7 to 85.4)100 (93.3 to 100)
Salk Type 3: Day 8592.6 (82.1 to 97.9)93.5 (82.1 to 98.6)96.0 (86.3 to 99.5)98.1 (89.9 to 100)
SecondaryGeometric Mean Titers (GMT) on Days 85, 365 and 393 in Infant Dose Ranging Cohort

GMT titers for poliovirus types 1, 2, and 3 for both Sabin and Salk strains will be reported.

Time frame:
Days 85, 365 and 393
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMT) on Days 85, 365 and 393 in Infant Dose Ranging Cohort
titerInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPV
Sabin Type 1: Day 8547.2 (28.2 to 78.8)105.6 (61.8 to 180.4)222.7 (130.6 to 379.7)155.0 (104.4 to 230.3)
Sabin Type 2: Day 8553.2 (34.4 to 82.3)119.7 (74.2 to 192.9)205.1 (138.9 to 303.0)268.1 (188.4 to 381.5)
Sabin Type 3: Day 85400.0 (267.3 to 598.4)748.2 (540.5 to 1035.7)844.6 (598.2 to 1192.5)533.8 (391.8 to 727.1)
Salk Type 1: Day 8511.7 (8.6 to 15.7)18.2 (11.5 to 28.9)27.5 (17.8 to 42.6)719.4 (520.9 to 993.7)
Salk Type 2: Day 8514.3 (9.7 to 21.2)22.4 (14.8 to 33.9)26.2 (18.2 to 37.6)400.1 (296.7 to 539.7)
Salk Type 3: Day 85139.7 (83.7 to 233.2)257.9 (160.0 to 415.6)361.2 (230.4 to 566.2)456.2 (317.3 to 656.0)
SecondaryVaccine Response Rate (VRR) on Day 393 in Infant Dose Ranging Cohort

VRR is defined as percentage of participants i) seronegative prior to booster vaccination (titer \<8) having a titer ≥8, or ii) seropositive prior to booster vaccination (titer ≥8) having a 4-fold rise in antibody titers.

Time frame:
Day 393

No measurements were reported for this outcome.

Adverse events

Collected over Up to Day 8 for Adults, Day 183 for Toddlers and Day 597 for Infants. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adult Lead-in Cohort: sIPV High Dose0/20 (0%)0/20 (0%)0/20 (0%)
Adult Lead-in Cohort: Placebo0/20 (0%)0/20 (0%)0/20 (0%)
Toddler Lead-in Cohort: sIPV High Dose0/30 (0%)0/30 (0%)8/30 (26.7%)
Toddler Lead-in Cohort: Reference IPV0/30 (0%)0/30 (0%)13/30 (43.3%)
Infant Dose Ranging Cohort: sIPV Low Dose0/59 (0%)8/59 (13.6%)17/59 (28.8%)
Infant Dose Ranging Cohort: sIPV Medium Dose1/60 (1.7%)5/60 (8.3%)17/60 (28.3%)
Infant Dose Ranging Cohort: sIPV High Dose0/60 (0%)5/60 (8.3%)19/60 (31.7%)
Infant Dose Ranging Cohort: Reference IPV1/60 (1.7%)8/60 (13.3%)20/60 (33.3%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventAdult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: PlaceboToddler Lead-in Cohort: sIPV High DoseToddler Lead-in Cohort: Reference IPVInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPV
PneumoniaInfections and infestations0/200/200/300/301/594/603/602/60
GastroenteritisInfections and infestations0/200/200/300/302/590/600/600/60
BronchiolitisInfections and infestations0/200/200/300/301/590/601/602/60
BronchitisInfections and infestations0/200/200/300/301/590/600/600/60
Urinary tract infectionInfections and infestations0/200/200/300/301/590/600/600/60
Milk allergyImmune system disorders0/200/200/300/301/590/600/600/60
TracheitisInfections and infestations0/200/200/300/301/590/600/600/60
Meningitis asepticInfections and infestations0/200/200/300/300/590/600/601/60
CyanosisCardiac disorders0/200/200/300/300/590/601/600/60
DeathGeneral disorders0/200/200/300/300/591/600/600/60
Most frequent other events
Most frequent other events
EventAdult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: PlaceboToddler Lead-in Cohort: sIPV High DoseToddler Lead-in Cohort: Reference IPVInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPV
NasopharyngitisInfections and infestations0/200/205/308/309/599/6013/6013/60
TonsillitisInfections and infestations0/200/200/300/307/597/604/605/60
InfluenzaInfections and infestations0/200/202/303/300/590/600/600/60
RhinitisInfections and infestations0/200/200/300/304/593/603/603/60
PyrexiaGeneral disorders0/200/201/302/300/590/600/600/60

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Adult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: PlaceboToddler Lead-in Cohort: sIPV High DoseToddler Lead-in Cohort: Reference IPVInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPVTotal
Mean34.9 ± 8.5635.1 ± 8.23——————35.0 ± 8.29
Age, Continuous
Age, Continuous(months)Adult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: PlaceboToddler Lead-in Cohort: sIPV High DoseToddler Lead-in Cohort: Reference IPVInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPVTotal
Mean——14.1 ± 0.9814.0 ± 1.02————14.0 ± 0.99
Age, Continuous
Age, Continuous(weeks)Adult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: PlaceboToddler Lead-in Cohort: sIPV High DoseToddler Lead-in Cohort: Reference IPVInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPVTotal
Mean————6.6 ± 0.676.5 ± 0.626.5 ± 0.686.5 ± 0.626.5 ± 0.65
Sex: Female, Male
Sex: Female, Male(Participants)Adult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: PlaceboToddler Lead-in Cohort: sIPV High DoseToddler Lead-in Cohort: Reference IPVInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPVTotal
Female1613131231332922169
Male47171829273138171
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: PlaceboToddler Lead-in Cohort: sIPV High DoseToddler Lead-in Cohort: Reference IPVInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPVTotal
American Indian or Alaska Native1813292958575558317
Asian000000000
Native Hawaiian or Other Pacific Islander000000000
Black or African American1611122216
White110011206
More than one race000000101
Unknown or Not Reported000000000
Region of Enrollment
Region of Enrollment(Participants)Adult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: PlaceboToddler Lead-in Cohort: sIPV High DoseToddler Lead-in Cohort: Reference IPVInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPVTotal
Panama2020303060606060340
Height
Height(centimeter (cm))Adult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: PlaceboToddler Lead-in Cohort: sIPV High DoseToddler Lead-in Cohort: Reference IPVInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPVTotal
Mean160.00 (147.0 to 178.0)161.45 (149.0 to 189.0)77.13 (72.0 to 85.0)76.53 (70.0 to 80.0)55.71 (35.8 to 63.0)56.29 (52.0 to 72.0)55.21 (36.3 to 60.0)56.21 (51.0 to 75.0)87.31 (51.0 to 189.0)
Weight
Weight(kilogram (kg))Adult Lead-in Cohort: sIPV High DoseAdult Lead-in Cohort: PlaceboToddler Lead-in Cohort: sIPV High DoseToddler Lead-in Cohort: Reference IPVInfant Dose Ranging Cohort: sIPV Low DoseInfant Dose Ranging Cohort: sIPV Medium DoseInfant Dose Ranging Cohort: sIPV High DoseInfant Dose Ranging Cohort: Reference IPVTotal
Mean74.30 (56.5 to 100.0)68.74 (41.5 to 98.0)10.21 (8.4 to 12.5)10.32 (7.5 to 15.3)4.94 (3.7 to 6.6)4.94 (3.4 to 6.1)4.89 (3.6 to 6.3)4.98 (3.2 to 5.9)22.91 (3.2 to 100.0)

2 further baseline measures are reported on the registry.

08

Study locations

4 sites
  • CEVAXIN - David
    Chiriqui, Panama
  • CEVAXIN Plaza Carolina - Ciudad de Panama
    Ciudad de Panama, Panama
  • CEVAXIN - 24 de Diciembre
    Panama, Panama
  • CEVAXIN - Chorrera
    Panama, Panama
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Apr 2018, 9 months.

Results were first posted in Jan 2020, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2017
First posted
Mar 28, 2017
StartActual
Jun 7, 2017
Primary completionActual
Apr 3, 2018
CompletionActual
Oct 18, 2018
Results first posted
Jan 31, 2020
Last update
Jan 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03092791
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 28, 2017
Start date
Jun 7, 2017
Primary completion
Apr 3, 2018
Completion
Oct 18, 2018
Results posted
Jan 31, 2020
Last update
Jan 31, 2020

Study contacts

Senior Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion